Top 5 private biotech companies in India

India is filled with biotech companies and a young, skilled workforce. Here is a sneak peek at India’s private healthcare biotech that has captured the imagination of investors in the past couple of years.

India has historically been known for its large IT, pharmaceutical and vaccine manufacturing sectors, but it is also a force to be reckoned with in the global biotechnology market. The country boasts about 5,000 biotech companies, and more than 4,000 start-ups. This startup count is It is expected to reach 10,000 by 2024.

With a large number of young and skilled workers, India has many ingredients to expand the number of biotech companies in the coming years. Add to this a large patient population for lifestyle related diseases such as type 2 diabetes, and there is great potential to generate innovations in healthcare.

We have compiled a shortlist of the top private biotechnology companies in India by checking out who have raised impressive money in the last few years. These companies conduct innovative research in healthcare and are primarily based in Mumbai and Bengaluru.

India Mumbai Shutterstock 1493970836
Photo / Elena Risko

Bugworks Research India Pvt Ltd

was established: 2014

headquarters: Bengaluru, India and Saratoga, United States

Bugworks has multiple locations in the US and Australia and has a research and development base in India. The company specializes in developing antibiotics that can treat growth Antimicrobial resistance crisis.

The main candidate antibiotic for Bugworks impedes the replication machinery of bacterial invasion. Additionally, the drug is designed to bypass bacteria’s natural resistance mechanisms, which can make it difficult for strains to become resistant to treatment.

The company is testing the antibiotic in phase I trials to treat multidrug-resistant infections in collaboration with the nonprofit CARB-X initiatives and the Global Antibiotic Research and Development Partnership (GARDP).

Bugworks is funding its own antibiotic research with a $18 million Series B round closing in February 2022. In addition, Bugworks will use the proceeds to fund preclinical development of a dual-acting cancer drug.

Epigeneres Biotech Private Limited

was established: 2012

headquarters: Mumbai

Epigeneres Biotech made headlines in January 2022 with a $6 million Series B funding round. The company is using the cash to develop a wide range of different technologies in its arsenal, including cancer tests, nanotechnology-based drugs, and nutrients.

Detecting cancer is Epigeneres’ latest endeavor. In 2021, the company teamed up with Singapore’s Tzar Labs to develop cancer diagnostics that screens for RNA molecules from tumors in the early stages of the disease. Epigeneres is preparing to launch a screening service in India based on technology.

Epigeneres also has DNA drugs in development to treat conditions ranging from infertility to kidney failure to autoimmune diseases. The company uses some form of nanotechnology to enhance drug delivery to target cells.

In addition, Epigeneres is working on small molecule drugs that can increase the number of stem cells in the body in the setting of regenerative medicine.

Eyestem

was established: 2016

headquarters: Bengaluru

In August 2022, Eyestem caught the eye of investors with a $6.4 million Series A round. The startup is working on cellular treatments for eye disorders, with a pioneering treatment in the pipeline for dry age-related macular degeneration (AMD).

There is currently no cure for dry AMD. In patients with this condition, cellular debris builds up in the eye, causing devastating inflammation of the retina. This leads to a loss of the retinal pigment epithelium, the layer of cells that supports the light-sensitive cells we need to see.

Eyestem is developing a turnkey stem cell therapy to replace the pigment cells in the retina. The biotech has allocated funds from its latest round of Series A to prepare its cell therapy for early-stage clinical trials.

Immuneel Therapeutics Private Limited

was established: 2019

headquarters: Bengaluru

Immuneel Therapeutics is making waves in the field of self-treatment CAR T-cell therapy, in which a patient’s immune T cells are removed, engineered in a lab to kill leukemia cells, and return them to the patient’s blood. CAR-T treatments are already available, but these complex and expensive treatments are currently limited to wealthier countries.

Immuneel’s mission is to develop accessible and affordable CAR-T treatments in India. To support this payment, the company raised $15 million in June 2022 in a Series A round.

The treatments in Immuneel’s pipeline target different types of leukemia in children and adult patients. When the company closed its first round, Immuneel began a phase two CAR-T therapy trial in what it claims is the first industry-sponsored CAR-T trial in India.

MedGenome

was established: 2013

headquarters: Bengaluru and Wilmington, United States

MedGenome has locations all over the world, with a large portion of its genetic testing operations and testing being located in and targeting India.

The company conducts research focused on genomics and diagnostic services for biopharmaceutical customers that can help develop drugs that treat cancer, diabetes, eye disease, and cardiovascular disease. To provide a rich data set, the company works with more than 500 hospitals in India.

MedGenome raised one of the Asia-Pacific region Biggest investment in biotechnology In August 2022 – a $50 million round led by Novo Holdings. The money will be used to increase access to genetic testing in emerging markets, which have fallen behind from the richer parts of the world.

MedGenome also aims to collect genomic data from a wide range of populations in Asia, which could provide a treasure trove of clinical insights into disease-related genes. In line with this goal, the company is a founding member of GenomeAsia 100K Initiativewhich will analyze the genomes of 100,000 people from a group of Asian populations to accelerate the development of precision medicine in this part of the world.

Leave a Comment